Shanghai Juncell Therapeutics

This early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…

This early-phase study tests a treatment called GC101 TIL for people with brain glioma, a type of brain cancer. Doctors take immune cells from the patient's own tumor, grow them in a lab, and then put them back into the patient. The goal is to see if this approach is safe and can…

This Phase 2 trial tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to fight the cancer. About 98 particip…

This phase II trial tests a new treatment for non-small cell lung cancer using immune cells taken from the patient's own tumor. The cells are grown in a lab and then infused back to attack the cancer. The study will enroll 28 adults and measure how well the treatment shrinks tumo…

This early-stage trial tests a personalized treatment called GC101 TIL for people with advanced non-small cell lung cancer that has not responded to standard treatments. The therapy uses immune cells taken from the patient's own tumor, multiplied in a lab, and then infused back i…

This early-phase trial tests a personalized therapy for people with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a sample of the patient's tumor, grow them into large numbers in a lab, and infuse them back into the patient. …

This early-phase trial tests a new therapy called GC203 TIL, which uses a patient's own immune cells that are genetically modified to better attack pancreatic cancer. Ten adults whose cancer has not responded to standard treatments will receive these cells after a short course of…

This trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…

This early-phase study tests a personalized cell therapy for people with advanced gastrointestinal tumors that have not responded to standard treatments. Doctors take immune cells from the patient's own tumor, grow them in a lab, and infuse them back after a short chemotherapy pr…

This early-phase trial tests a personalized therapy where immune cells (TILs) are taken from a patient's own tumor, multiplied in a lab, and infused back into the body to attack the cancer. The study includes both natural and gene-edited TILs and enrolls 30 adults with advanced s…

This early-phase trial tests a therapy made from a patient's own tumor-fighting immune cells (TILs) for advanced melanoma. Doctors take TILs from a tumor sample, grow them in the lab, and infuse them back after a short chemotherapy course. The study aims to see if this approach i…

This early-phase trial is testing a treatment called tumor-infiltrating lymphocytes (TILs) in 50 people with advanced liver or pancreatic cancers that have not responded to standard treatments. Doctors take immune cells from a patient's tumor, grow them in a lab, and then infuse …

This study tests a treatment called TIL therapy for people with advanced breast cancer who have run out of standard options. Doctors take immune cells from a patient's own tumor, grow them in a lab, and put them back into the body to attack the cancer. The goal is to see if it is…

This early-phase study tests a new treatment called GC201 TIL for people with advanced gynecologic cancers that have not responded to standard therapies. Doctors take immune cells from the patient's own tumor, modify them to better fight cancer, and then infuse them back after a …

This early-phase study tests a new treatment called GC203 TIL for people with advanced solid tumors (cancers in organs like the breast, lung, or gut) that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to bet…